Tarsus expects $715M-$730M 2026 XDEMVY sales while deferring Europe and Japan filings
Open the sourceReported by Seeking Alpha, seekingalpha.com, 4 November 2026
50Impact 50 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at seekingalpha.com.
Named in this story
XDEMVY, Tarsus Pharmaceuticals, Europe, Japan